LAG3 and metastatic melanoma: Another issue to be solved would be to better evaluate the time to relapse after last treatment, and appropriately adjust next treatments’ ICI might be an option, according to the results provided from the combination of anti-LAG-3 and anti-PD-1 leading to significant benefits in recurrent/metastatic melanoma patients.